VEGFA and glioblastoma: This invasion is more important in vascular endothelial growth factor (VEGF)-deficient glioblastoma cells (Blouw et al., 2003; Du et al., 2008) and brain tumor xenografts treated with anti-VEGF blocking antibodies such as bevacizumab (Rubenstein et al., 2000; Kunkel et al., 2001; de Groot et al., 2010; Carbonell et al., 2013; Baker et al., 2014).